Bioxytran, Inc. (OTCMKTS:BIXT – Get Free Report) shares fell 2.1% on Tuesday . The company traded as low as $0.12 and last traded at $0.13. 134,297 shares changed hands during trading, a decline of 43% from the average session volume of 234,412 shares. The stock had previously closed at $0.13.
Bioxytran Stock Down 2.1%
The company has a market cap of $11.19 million, a P/E ratio of -12.57 and a beta of 1.78. The firm’s 50 day moving average is $0.15 and its two-hundred day moving average is $0.12.
Bioxytran (OTCMKTS:BIXT – Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.02) EPS for the quarter.
About Bioxytran
Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.
Further Reading
- Five stocks we like better than Bioxytran
- The Significance of Brokerage Rankings in Stock Selection
- AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway
- How to Evaluate a Stock Before Buying
- Casey’s Surges on Strong Q4, More Gains Likely Ahead
- Why Are Stock Sectors Important to Successful Investing?
- Government Mandate Sends eVTOL Stocks Flying
Receive News & Ratings for Bioxytran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioxytran and related companies with MarketBeat.com's FREE daily email newsletter.
